Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Aquestive Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Aquestive Therapeutics announced earnings per share of $-0.230 on revenue of $11.46M. Analysts polled by Investing.com EPS of $-0.301 on revenue of $11.04M.
Aquestive Therapeutics 's are down 39.79% and is trading at $0.875 , still down 86.33% from its 52 week high of $6.40 set on Monday, November 29, 2021.
Aquestive Therapeutics follows other major Healthcare sector earnings this month
Aquestive Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar